Cheung Kong Group

CK Life Sciences Int'l., (Holdings) Inc. is the dedicated life sciences arm of the CK Hutchison Group (formerly known as the Cheung Kong Group), a major global conglomerate based in Hong Kong. The company focuses on the research, development, and commercialization of products across health, agriculture, and environmental sectors. Its pharmaceutical pipeline is highlighted by sevileucel-T, a Phase 3 polyvalent vaccine for melanoma developed by its subsidiary Polynoma, and Halneuron, a tetrodotoxin-based treatment for cancer pain through WEX Pharmaceuticals. CK Life Sciences also maintains a dominant position in the global nutraceutical market, significantly bolstered by its 2023 acquisition of the Australian health supplement giant Blackmores. The company is listed on the Hong Kong Stock Exchange and leverages the extensive international network of its parent group to drive growth in the life sciences sector.